Opsens – First use of its FFR products in the U.S.

Quebec City, Quebec, November 11, 2015 – Opsens Inc. (“Opsens” or the “Company”) (TSXV:OPS) (OTCQX:OPSSF) is pleased to announce that the OptoWire and OptoMonitor, its products to measure Fractional Flow Reserve (“FFR”), were used for the first time in the United States by Dr. Morton J. Kern and Dr. Arnold Seto at the University of California, Irvine and VA Long Beach, California. Opsens’ FFR products are designed for the diagnostic of the functional severity of coronary stenoses and to guide their treatment.

“Dr. Kern has been working with Opsens for many years. We are proud to see Dr. Kern, one of the most renowned U.S. and worldwide cardiologists, use our products in his practice,” said Claude Belleville, Opsens’ Vice President, Medical Devices.

“It is exciting to see the introduction of a new wire technology such as the OptoWire and its performance for the measurement of FFR. The arrival of a ”near” workhorse fiber optic guidewire like the OptoWire in the FFR market is a positive step for interventional cardiologists and will be helpful to the FFR procedure. Using the OptoWire in several patients, some of them with complex disease, demonstrated very reliable measurements with an impressive zero drift performance. Also, we noticed the reliability of the optical connection with a stable connect/re-connect capability without loss of signal stability,” said Dr. Kern.

“We are confident that the positive response to the OptoWire, expressed by key players in the FFR field, paves the way for a very successful market launch, a market that reached US$300 million in 2014 and is expected to reach US$1 billion medium term,” said Louis Laflamme, President and CEO of Opsens.

About Opsens Inc. (www.opsens.com or www.opsensmedical.com)

Opsens focuses mainly on the measure of Fractional Flow Reserve (“FFR”) in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities. The Company develops, manufactures and installs innovative fibre optic sensing solutions for critical applications such as the monitoring of oil wells and other demanding industrial applications.

Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.